Ads
related to: ovarian cancer approved drugs
Search results
Results from the WOW.Com Content Network
(Reuters) -The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's "guided missile" cancer therapy, Elahere, for patients with a type of ovarian ...
In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
Rucaparib: On December 19, 2016, the US FDA granted accelerated approval for previously treated BRCA-mutant ovarian cancer. [8] In April 2018 it was granted FDA approval. Niraparib: In March 2017 approved by US FDA for epithelial ovarian, fallopian tube, and primary peritoneal cancer. [9] [10] Inhibitor of PARP1 and PARP2. [11]
The U.S. Food and Drug Administration (FDA) approved a treatment developed by AstraZeneca (AZN) and Merck Co. (MRK) for advanced ovarian cancer.The FDA approved the ovarian drug Lynparza to be ...
Scientists from Purdue University designed and developed OTL38 and licensed it to On Target Laboratories in 2013. [9] [10] The safety and effectiveness of pafolacianine was evaluated in a randomized, multi-center, open-label study of women diagnosed with ovarian cancer or with high clinical suspicion of ovarian cancer who were scheduled to undergo surgery.
Ads
related to: ovarian cancer approved drugs